Before semaglutide, tirzepatide, and retatrutide took the world by storm, there was Liraglutide, the first GLP-1 receptor agonist to demonstrate that manipulating incretin hormones could dramatically improve weight loss, glucose control, and metabolic function. Marketed under the brand names Victoza and Saxenda, liraglutide paved the way for the next generation of GLP-based drugs that are […]Read More